ADMA Biologics Inc. (ADMA)
ADMA Biologics Statistics
Share Statistics
ADMA Biologics has 236.39M shares outstanding. The number of shares has increased by 3.58% in one year.
| Shares Outstanding | 236.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 228.49M |
| Failed to Deliver (FTD) Shares | 129 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 12.18M, so 5.15% of the outstanding shares have been sold short.
| Short Interest | 12.18M |
| Short % of Shares Out | 5.15% |
| Short % of Float | 5.33% |
| Short Ratio (days to cover) | 4.55 |
Valuation Ratios
The PE ratio is -35.85 and the forward PE ratio is 30.25.
| PE Ratio | -35.85 |
| Forward PE | 30.25 |
| PS Ratio | 3.92 |
| Forward PS | 6.4 |
| PB Ratio | 7.49 |
| P/FCF Ratio | 265.09 |
| PEG Ratio | n/a |
Enterprise Valuation
ADMA Biologics Inc. has an Enterprise Value (EV) of 1.10B.
| EV / Earnings | -39.04 |
| EV / Sales | 4.27 |
| EV / EBITDA | 215.32 |
| EV / EBIT | 50.96 |
| EV / FCF | 288.67 |
Financial Position
The company has a current ratio of 5.16, with a Debt / Equity ratio of 1.05.
| Current Ratio | 5.16 |
| Quick Ratio | 1.69 |
| Debt / Equity | 1.05 |
| Total Debt / Capitalization | 51.12 |
| Cash Flow / Debt | 0.06 |
| Interest Coverage | 0.86 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is 7.82%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.09% |
| Return on Capital (ROIC) | 7.82% |
| Revenue Per Employee | 413.81K |
| Profits Per Employee | -45.25K |
| Employee Count | 624 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 0.98 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 203.75% in the last 52 weeks. The beta is 0.65, so ADMA Biologics 's price volatility has been higher than the market average.
| Beta | 0.65 |
| 52-Week Price Change | 203.75% |
| 50-Day Moving Average | 18.72 |
| 200-Day Moving Average | 14.79 |
| Relative Strength Index (RSI) | 39.13 |
| Average Volume (20 Days) | 2.97M |
Income Statement
In the last 12 months, ADMA Biologics had revenue of 258.21M and earned -28.24M in profits. Earnings per share was -0.13.
| Revenue | 258.21M |
| Gross Profit | 88.94M |
| Operating Income | 21.63M |
| Net Income | -28.24M |
| EBITDA | 5.12M |
| EBIT | 21.63M |
| Earnings Per Share (EPS) | -0.13 |
Balance Sheet
The company has 51.35M in cash and 141.42M in debt, giving a net cash position of -90.07M.
| Cash & Cash Equivalents | 51.35M |
| Total Debt | 141.42M |
| Net Cash | -90.07M |
| Retained Earnings | -506.26M |
| Total Assets | 390.62M |
| Working Capital | 273.30M |
Cash Flow
In the last 12 months, operating cash flow was 8.80M and capital expenditures -4.98M, giving a free cash flow of 3.82M.
| Operating Cash Flow | 8.80M |
| Capital Expenditures | -4.98M |
| Free Cash Flow | 3.82M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 34.44%, with operating and profit margins of 8.38% and -10.94%.
| Gross Margin | 34.44% |
| Operating Margin | 8.38% |
| Pretax Margin | -10.94% |
| Profit Margin | -10.94% |
| EBITDA Margin | 1.98% |
| EBIT Margin | 8.38% |
| FCF Margin | 1.48% |
Dividends & Yields
ADMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.8% |
| FCF Yield | 0.1% |
Analyst Forecast
The average price target for ADMA is $22.5, which is 39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.5 |
| Price Target Difference | 39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 15.44 |
| Piotroski F-Score | 8 |